Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity.

OBJECTIVE To correlate serum levels of the soluble adhesion molecules intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin, and P-selectin with (a) clinical disease activity and progression and (b) the in situ expression and distribution of these adhesion molecules in lesional skin, in patients with systemic sclerosis (SSc). METHODS Serum samples from 12 SSc patients and 36 healthy controls were examined by enzyme-linked immunosorbent assay. Immunohistologic staining was carried out on cryostat sections of lesional skin. RESULTS Patients whose SSc was in the early inflammatory stage or who had prominent disease progression showed elevated serum levels of soluble adhesion molecules. Serum levels correlated positively with the expression of these molecules on endothelial cells and fibroblasts in lesional skin. CONCLUSION Serum levels of soluble ICAM-1, VCAM-1, P-selectin, and, to a lesser degree, E-selectin correlate well with their in situ activity and with clinical disease activity. These parameters therefore provide a useful tool for the characterization of disease stage, progression, and prognosis in SSc.

[1]  P. von den Driesch,et al.  Cellular adhesion antigen modulation in purpura pigmentosa chronica. , 1994, Journal of the American Academy of Dermatology.

[2]  G. Hunder,et al.  Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. , 1993, The Journal of rheumatology.

[3]  T. Kupper,et al.  Differential induction of intercellular adhesion molecule‐1 in human skin by recombinant cytokines , 1993, Journal of cutaneous pathology.

[4]  O. Hornstein,et al.  Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. , 1992, Journal of the American Academy of Dermatology.

[5]  W. Sterry,et al.  Infiltration of both T cells and neutrophils in the skin is accompanied by the expression of endothelial leukocyte adhesion molecule-1 (ELAM-1): an immunohistochemical and ultrastructural study. , 1992, The Journal of investigative dermatology.

[6]  M. Makgoba,et al.  Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders , 1991, The Lancet.

[7]  T. V. Gopal,et al.  Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions , 1991, The Journal of cell biology.

[8]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[9]  Rodger P. McEver,et al.  Rapid neutrophil adhesion to activated endothelium mediated by GMP-140 , 1990, Nature.

[10]  M. Meurer,et al.  Systemic scleroderma. Clinical and pathophysiologic aspects. , 1988, Journal of the American Academy of Dermatology.

[11]  O. Braun-falco,et al.  [Clinical aspects of progressive systemic scleroderma (PSS). Multicenter studies of 194 patients]. , 1986, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[12]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[13]  M P Bevilacqua,et al.  Endothelial-leukocyte adhesion molecules. , 1993, Annual review of immunology.

[14]  R. Strieter,et al.  In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. , 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.